These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

997 related items for PubMed ID: 17132756

  • 21. Acne severity and the Global Acne Grading System in polycystic ovary syndrome.
    Hacivelioglu S, Gungor AN, Gencer M, Uysal A, Hizli D, Koc E, Cosar E.
    Int J Gynaecol Obstet; 2013 Oct; 123(1):33-6. PubMed ID: 23948280
    [Abstract] [Full Text] [Related]

  • 22. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study.
    Dalamaga M, Papadavid E, Basios G, Vaggopoulos V, Rigopoulos D, Kassanos D, Trakakis E.
    J Am Acad Dermatol; 2013 Dec; 69(6):922-30. PubMed ID: 24120563
    [Abstract] [Full Text] [Related]

  • 23. [Contribution of hyperandrogenism to the development of metabolic syndrome in obese women with polycystic ovary syndrome].
    Rehme MF, Pontes AG, Corrente JE, Franco JG, Pontes A.
    Rev Bras Ginecol Obstet; 2013 Dec; 35(12):562-8. PubMed ID: 24500511
    [Abstract] [Full Text] [Related]

  • 24. Modified Ferriman-Gallwey hirsutism score and androgen levels in Turkish women.
    Coskun A, Ercan O, Arikan DC, Özer A, Kilinc M, Kiran G, Kostu B.
    Eur J Obstet Gynecol Reprod Biol; 2011 Feb; 154(2):167-71. PubMed ID: 21041013
    [Abstract] [Full Text] [Related]

  • 25. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, Douhat S, Mudassar S, Jan VM, Rashid F.
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [Abstract] [Full Text] [Related]

  • 26. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
    Coskun A, Arikan T, Kilinc M, Arikan DC, Ekerbiçer HÇ.
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls.
    Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrøm V, Flyvbjerg A, Hermann AP.
    Eur J Endocrinol; 2006 Aug; 155(2):337-45. PubMed ID: 16868149
    [Abstract] [Full Text] [Related]

  • 28. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T, Dehghan-Kooshkghazi M.
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [Abstract] [Full Text] [Related]

  • 29. Hyperandrogenemia association with acne and hirsutism severity in Croatian women with polycystic ovary syndrome.
    Pavičić Baldani D, Škrgatić L, Bukvić Mokos Z, Trgovčić I.
    Acta Dermatovenerol Croat; 2013 Feb; 21(2):105-12. PubMed ID: 24001418
    [Abstract] [Full Text] [Related]

  • 30. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
    Münzker J, Hofer D, Trummer C, Ulbing M, Harger A, Pieber T, Owen L, Keevil B, Brabant G, Lerchbaum E, Obermayer-Pietsch B.
    J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
    [Abstract] [Full Text] [Related]

  • 31. Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome.
    Franik G, Bizoń A, Włoch S, Kowalczyk K, Biernacka-Bartnik A, Madej P.
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4411-4418. PubMed ID: 30058676
    [Abstract] [Full Text] [Related]

  • 32. Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Glintborg D.
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
    [Abstract] [Full Text] [Related]

  • 33. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance.
    Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C.
    Horm Res; 2004 Apr; 62(6):283-7. PubMed ID: 15542929
    [Abstract] [Full Text] [Related]

  • 34. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients.
    Karadağ C, Yoldemir T, Gogas Yavuz D.
    Gynecol Endocrinol; 2017 Mar; 33(3):234-237. PubMed ID: 27908213
    [Abstract] [Full Text] [Related]

  • 35. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
    Patlolla S, Vaikkakara S, Sachan A, Venkatanarasu A, Bachimanchi B, Bitla A, Settipalli S, Pathiputturu S, Sugali RN, Chiri S.
    Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
    [Abstract] [Full Text] [Related]

  • 36. Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis.
    Amiri M, Ramezani Tehrani F, Nahidi F, Bidhendi Yarandi R, Behboudi-Gandevani S, Azizi F.
    Clin Endocrinol (Oxf); 2017 Sep; 87(3):217-230. PubMed ID: 28575537
    [Abstract] [Full Text] [Related]

  • 37. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
    Sobbrio GA, Granata A, D'Arrigo F, Arena D, Panacea A, Trimarchi F, Granese D, Pullè C.
    Acta Eur Fertil; 1990 Sep; 21(3):139-41. PubMed ID: 2149912
    [Abstract] [Full Text] [Related]

  • 38. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia.
    Pall M, Azziz R, Beires J, Pignatelli D.
    Fertil Steril; 2010 Jul; 94(2):684-9. PubMed ID: 19726039
    [Abstract] [Full Text] [Related]

  • 39. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C, Arriaga M, Arechavaleta-Velasco F, Moran S.
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [Abstract] [Full Text] [Related]

  • 40. Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome.
    Kajaia N, Binder H, Dittrich R, Oppelt PG, Flor B, Cupisti S, Beckmann MW, Mueller A.
    Eur J Endocrinol; 2007 Oct; 157(4):499-507. PubMed ID: 17893265
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.